TY - JOUR
T1 - Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis
T2 - ATTEST–AMPLE network randomized trial
AU - Christensen, Robin Daniel Kjersgaard
AU - Tarp, Simon
AU - Furst, Daniel E
AU - Kristensen, Lars Erik
AU - Bliddal, Henning
PY - 2013/12
Y1 - 2013/12
N2 - Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of analysis is to combine evidence from direct and indirect sources into one overall objective. The meta-data set included results from the ATTEST and AMPLE studies. Major outcomes concerned the benefits and harm after 1 year on therapy; coprimary outcomes patients achieving a 50% response on the ACR improvement criteria, extracted from the papers, and the number of withdrawals related to adverse events, respectively. Statistical analyses were based on mixed-effects logistic regression, using an arm-based, random-effects model respecting randomization within each study. Following indirect comparisons across all three groups, we conclude that infliximab, at the recommended dose, is less efficacious than abatacept and potentially also adalimumab, and that adalimumab and abatacept are approximately equivalent both in terms of benefit and short-term harm assessment (up to 1 year).
AB - Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of analysis is to combine evidence from direct and indirect sources into one overall objective. The meta-data set included results from the ATTEST and AMPLE studies. Major outcomes concerned the benefits and harm after 1 year on therapy; coprimary outcomes patients achieving a 50% response on the ACR improvement criteria, extracted from the papers, and the number of withdrawals related to adverse events, respectively. Statistical analyses were based on mixed-effects logistic regression, using an arm-based, random-effects model respecting randomization within each study. Following indirect comparisons across all three groups, we conclude that infliximab, at the recommended dose, is less efficacious than abatacept and potentially also adalimumab, and that adalimumab and abatacept are approximately equivalent both in terms of benefit and short-term harm assessment (up to 1 year).
U2 - 10.2217/ijr.13.62
DO - 10.2217/ijr.13.62
M3 - Journal article
SN - 1758-4272
VL - 8
SP - 647
EP - 655
JO - International Journal of Clinical Rheumatology
JF - International Journal of Clinical Rheumatology
IS - 6
ER -